Bionure is an academic spin-off from IDIBAPS – Hospital Clinic of the University of Barcelona and the Spanish National Council CSIC.

Based on more than 15-year of research in neuroprotection, the company claims to develop new first-in-class disease-modifier drugs able to slow down, stop or reverse the damaging process affecting neurons.

Its lead program, BN201, demonstrated neuroprotective activity in several preclinical models and has successfully completed a clinical Phase I study in the UK.

In 2020, the company plans to start a Phase II proof-of-concept trial in optic neuritis and multiple sclerosis, to prove the efficacy of the compound in patients affected by neuronal damage.